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INTRODUCTION
Patients with severe chronic obstructive pulmonary disease (COPD) suffer from high morbidity and mortality (1) (2) . Long-term oxygen therapy (LTOT) improves the survival time in the most severe COPD with chronic hypoxia (P a O 2 < 7.3 kPa), as was shown in two randomized controlled trials published in the early 1980s (3-4).
A later study of a less selective group of patients showed shorter survival times than in the previous randomized controlled trials, mainly because the less selected patients were older and had more co-morbidities (1) . Both age and co-morbidity are important predictors of mortality in COPD (5) (6) .
In recent decades the demography of patients starting LTOT for COPD has changed markedly. In Sweden, the mean age of patients starting LTOT increased from approximately 66 to 73 years between 1987 and 2000 (7) . There has also been a significant increase in the proportion of women; in fact the majority of patients starting LTOT are now women (7) . The prevalence of cardiovascular disease, which is increased in severe COPD, has been shown to rise with age (6, (8) (9) . Thus, the burden of cardiovascular disease and other co-morbidities might have increased, but it is unknown whether mortality and causes of death have changed over time in severe COPD. We hypothesize that the overall mortality has increased, and that over time more patients die from non-respiratory causes, such as cardiovascular disease.
The aim of this national prospective study was to evaluate whether there have been any time trends in overall and cause-specific mortality in patients on LTOT due to COPD, with special attention paid to mortality from cardiovascular disease. were eligible for inclusion in the study. Excluded were patients who started LTOT more than once (n=71) or were incorrectly registered (n=18). All other patients were followed prospectively with cause of death as the primary outcome, as previously reported (2) .
Baseline data were collected at the start of LTOT on arterial gas tension of oxygen (P a O 2 ) and carbon dioxide (P a CO 2 ) when breathing air and during oxygen therapy, forced expiratory volume in one second (FEV 1 ), forced vital capacity (FVC), smoking history (never, past or current smoking), the prescribed oxygen dose, the prescribed duration of oxygen treatment per day and WHO performance status (10) .
The underlying causes of death were obtained from the Swedish Causes of Death Register, coded according to the ninth (before 1997) and tenth revisions of the International Classification of Disease (ICD) (11-12). The definitions and grouping of the diagnosis entities have been described elsewhere (2).
All patients gave their informed consent to participate. The study was approved by all ethics committees in Sweden, the Swedish National Board of Health and Welfare, and the Data Inspection Board.
Statistical methods
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Baseline data were summarized using mean ± SD and percentages for continuous and categorical variables respectively. Changes in baseline data with calendar year of starting LTOT (start year) were described using linear regression for continuous and logistic regression for categorical variables.
Time under risk was defined as the time from starting LTOT until death, withdrawal of LTOT or 31 December 2004, whichever came first.
The change in overall mortality rate by starting year was evaluated using Cox regression (13).
Changes in absolute risk of death for different causes of death (absolute cause-specific mortality) by starting year were evaluated by the proportional hazards model of Fine and Gray, which addresses the issue of competing risks (14) . Overall and absolute cause-specific mortality were presented unadjusted and adjusted for age, sex, P a O 2 air, smoking history and WHO performance status at baseline. In the adjusted analysis, WHO performance status was included because it predicted missing data in P a O 2 air, and thereby helped to avoid consequent bias in the regression estimates when analyzing complete cases only (15) .
Furthermore, the excess mortality, defined as the cause-specific mortality of the cohort as compared with that of the Swedish general population standardized for age, sex and calendar year, was expressed as standardized mortality rates (SMRs). Trends in SMRs by calendar year, adjusted for age and sex, were estimated using Poisson modelling (16) . In all analyses, mortality estimates were tabulated for diagnosis entities accounting for more than 1% of total deaths. All statistical tests were two-sided and P-values below the standard value of 0.05 were considered statistically significant. All confidence intervals were 95%-intervals.
All statistical analyses were performed with Stata version 11.0 (StataCorp LP; College Station, TX).
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RESULTS
A total of 7,628 patients, 4,027 women and 3,601 men, were included in the study. No patient was lost to follow up. LTOT was withdrawn prior to death in 522 (6.8%) patients, owing to improvement in oxygenation (n=170), poor compliance (n=31) or for other reasons (n=321).
Baseline data are shown in Table 1 . There was a pronounced increase in the proportion of women and in the mean age of patients starting LTOT during the study period. The mean FEV 1 , FVC, and the level of P a O 2 and P a CO 2 at baseline, both breathing ambient air and on oxygen, remained relatively constant. A total of 73% of the patients had P a O 2 < 7.3 kPa on air, and this proportion did not change over time (P=0.324).
Overall mortality rate
The median observation time was 1.71 years (range 0-17.97), generating 18,126.6 personyears at risk of death for the cohort as a whole. A total of 5,457 patients, 2,748 women and 2,709 men, died during follow up, resulting in a crude overall mortality rate of 30.1 deaths per 100 person-years (95% CI, 29.3-30.9).
There was a significant increase in the crude overall mortality of 1.6% (95% CI, 0.9-2.2; P<0.001) per year. Between 1987 and 2004, the crude mortality rate increased by a total of 33.1% (95% CI, 17.5-48.0). However, after adjusting for age, sex, P a O 2 breathing air, smoking history and WHO performance status, there was no significant time trend in the overall mortality rate, as shown in Table 2 .
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Absolute cause-specific mortality
The most common causes of death were respiratory (n=3885; 71%), circulatory (n=847; 16%), cancer (n=414; 7.6%) and digestive organ disease (n=62; 1.1%). The autopsy rate for the cohort declined from 16% 1987-1991 to 8% 2000-2004.
Time trends in crude and adjusted absolute cause-specific mortality are listed in Table 3 .
Crude mortality decreased for respiratory disease and increased for non-respiratory causes, including lung cancer, digestive organ disease and ischemic heart disease. 
Excess mortality (SMR)
As shown in Table 4 , excess mortality increased over time both overall, as well as for respiratory disease, cancer, digestive and circulatory disease, including ischemic heart disease.
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DISCUSSION
The main findings are that the crude overall mortality is increasing over time for patients starting LTOT for COPD, with a shift from respiratory causes and lung cancer to more circulatory causes of death, including ischemic heart disease. Furthermore, the excess mortality is increasing markedly both overall and for cardiovascular disease. This is, to the authors' knowledge, the first study of changes in cause-specific mortality over time in severe COPD. It is known from previous studies that in oxygen-dependent COPD, a substantial proportion of patients die from non-respiratory causes (17) , and that patients starting LTOT today are older, have more co-morbidity and higher overall mortality than the patients in the original randomized trials (1, (3) (4) 7) . This study extends the previous observations by showing that although most deaths are still attributed to respiratory disease, mortality and causes of death have changed in recent decades in oxygen-dependent COPD, with increasing mortality from non-respiratory causes.
The strength of the present study is the inclusion of a large national cohort of patients starting LTOT for COPD. The coverage of the register has been validated to some 85% of the total number of patients starting LTOT in Sweden (18) . The loss of data applies to entire counties owing to temporary shortages of staff, and is not likely to have been selective. Furthermore, no patient was lost to follow up. The findings in the present study are therefore likely to have high validity for clinical practice.
Nevertheless, the mortality estimates should be interpreted with some caution since they are based on data from death certificates. The cause-specific estimates could be affected by changes over time in diagnostics as well as changes in coding and classification of the causes of death by physicians and in the Swedish Causes of Death Register. However, the change from ICD9 to ICD-10 in 1997 is unlikely to have affected the reliability of the results, Page 8 of 22 8 according to a analysis performed by the Swedish National Board of Health and Welfare (19) . In our opinion, the possible bias does not substantially affect the internal or external validity of the present study.
When considering possible explanations for the observed time trends in mortality, two striking facts are the increase in the proportion of women and the age of the patients starting LTOT. These changes might partly be attributable to changes in the smoking habits of the Swedish population (7) . Since the 1970s, the rate of active smokers and the amount of smoking has decreased for both sexes, but less in women than in men (20). Most, but not all (21) , studies indicate that women might be more vulnerable to the adverse effects of smoking than men (22) (23) (24) , and the proportion of ever-smokers has increased more in women than in men (20). As a result, the majority of patient starting LTOT for COPD are now women.
Owing to less total tobacco exposure, the decline in lung function is delayed and both men and women are older when they require LTOT (7). Improved survival for other diseases, most notably cardiovascular disease (25), can also have increased the number of elderly patients with COPD eligible for LTOT, as well as the prevalence of co-morbidity. In addition, over time as LTOT has become more established, physicians might have become less reluctant to prescribe LTOT to older patients with more co-morbidity, even if this patient category was not included in the original randomized trials (3-4).
In the multiple regression analysis, the rising age explained most of the increase in crude mortality overall and for circulatory disease. Interestingly, the concomitant increase in overall excess mortality, which is age-standardized, indicates that the association between age and mortality might largely be due to increased morbidity rather than the effect of aging itself.
In our view, the mechanism underpinning the increasing overall and non-respiratory mortality is that the patients have a progressively higher burden of co-morbidity and become more Page 9 of 22 9 vulnerable with increasing age. This hypothesis is supported by the previous observations that in severe COPD, co-morbidity is prevalent (5) (6) 8) , increases further with age (6, 26) , and is a strong predictor of mortality (5) (6) 27) . The remaining time trends in mortality for respiratory and non-respiratory disease after adjusting might be due to residual co-morbidity not accounted for in the multiple regression analysis.
Some additional findings deserve mentioning. The decreasing mortality for COPD and lung cancer might in part be attributed to improved treatment, but may also be a reciprocal effect of the increasing mortality from non-respiratory diseases. The lack of increase in mortality for heart failure might be explained by advances in the treatment of heart failure over the last decades, or by the particular difficulty in differentiating heart failure from the respiratory disease in severe COPD. Thus heart failure might be under-reported as the cause of death, and whether there has been any trend in mortality for heart failure remains uncertain.
Excess mortality consists of a comparison of the mortality trends in the study group with the mortality trends in the general population. The excess mortality decreased for COPD since the mortality from COPD decreased among the study participants, but increased markedly in the general population during the study period (25). For cardiovascular disease, the development was the opposite. The mortality from ischemic heart disease declined by more than 50% between 1986 and 2002 in the general Swedish population (25). According to a recent study, 55% of the decline was attributable to risk factor reductions, such as decreased smoking and total serum cholesterol, and 36% of the decline was attributable to medical and interventional treatments (28) . However, it seems as if patients with severe COPD have not benefited from these improvements, since the excess mortality for ischemic heart disease has increased in our patient cohort, and therefore lose progressively more years of life than the general population.
This highlights the importance of promoting multidisciplinary risk factor modifications as well as of optimizing the diagnostics and treatment of co-morbidities in COPD.
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In conclusion, the present study supports the important prognostic role of co-morbidity in oxygen-dependent COPD and shows that mortality has increased for non-respiratory causes, such as cardiovascular disease. Figure 1 . Changes in the adjusted absolute cause-specific mortality for the main diagnosis groups between 1987 and 2004 in patients on long-term oxygen therapy for COPD. Mortality was adjusted for age, sex, P a O 2 breathing air, smoking history and WHO performance status at baseline. Time trends were significant for respiratory (P<0.001) and non-respiratory causes (P=0.013), but not for the subgroups cancer (P=0.101) or circulatory disease (P=0.328). 
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